| The L1TD1 protein interactome reveals the importance of post-transcriptional regulation in human pluripotency MR Emani, E Närvä, A Stubb, D Chakroborty, M Viitala, A Rokka, ... Stem cell reports 4 (3), 519-528, 2015 | 23 | 2015 |
| Transcriptional repressor HIC1 contributes to suppressive function of human induced regulatory T cells U Ullah, SBA Andrabi, SK Tripathi, O Dirasantha, K Kanduri, S Rautio, ... Cell reports 22 (8), 2094-2106, 2018 | 20 | 2018 |
| Receptor tyrosine kinase profiling of ischemic heart identifies ROR1 as a potential therapeutic target J Heliste, A Jokilammi, I Paatero, D Chakroborty, C Stark, T Savunen, ... BMC cardiovascular disorders 18 (1), 1-12, 2018 | 7 | 2018 |
| An unbiased in vitro screen for activating epidermal growth factor receptor mutations D Chakroborty, KJ Kurppa, I Paatero, VK Ojala, M Koivu, MZ Tamirat, ... Journal of Biological Chemistry 294 (24), 9377-9389, 2019 | 6 | 2019 |
| Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin E Narvi, K Vaparanta, A Karrila, D Chakroborty, S Knuutila, A Pulliainen, ... Scientific reports 8 (1), 1-13, 2018 | 6 | 2018 |
| L1TD1-a prognostic marker for colon cancer D Chakroborty, MR Emani, R Klén, C Böckelman, J Hagström, C Haglund, ... BMC cancer 19 (1), 1-9, 2019 | 4 | 2019 |
| L1td1 as predictive biomarker of colon cancer D Chakroborty, EM Reddy, ELO Laura, R Lahesmaa, A Ristimäki, ... US Patent App. 17/058,926, 2021 | | 2021 |
| Screen for actionable ERBB3 mutations MK Koivu, D Chakroborty, KJ Kurppa, K Elenius Cancer Research 81 (13 Supplement), 2424-2424, 2021 | | 2021 |
| An unbiased in vivo screen for activating EGFR mutations D Chakroborty, KJ Kurppa, K Elenius Cancer Research 81 (13 Supplement), 2299-2299, 2021 | | 2021 |
| Characterizing the oncogenic activity of ERBB4 mutations and their sensitivity to neratinib P Suominen, D Chakroborty, KJ Kurppa, I Diala, LD Eli, AS Lalani, ... Cancer Research 81 (13 Supplement), 2420-2420, 2021 | | 2021 |
| Identification of Predictive ERBB Mutations by Leveraging Publicly Available Cell Line Databases MKA Koivu, D Chakroborty, MZ Tamirat, MS Johnson, KJ Kurppa, ... Molecular Cancer Therapeutics 20 (3), 564-576, 2021 | | 2021 |
| iSCREAM-an unbiased pipeline to screen for activating kinase mutations D Chakroborty, KJ Kurppa, I Paatero, LL Elo, K Elenius Cancer Research 79 (13 Supplement), 1780-1780, 2019 | | 2019 |
| In silico screen for predictive ERBB mutations M Hakanen, D Chakroborty, K Kurppa, K Elenius EUROPEAN JOURNAL OF CANCER 103, E67-E67, 2018 | | 2018 |
| A pipeline to identify driver mutations D Chakroborty, K Kurppa, I Paatero, L Elo, K Elenius Cancer Research 78 (13 Supplement), 3500-3500, 2018 | | 2018 |
| Receptor Tyrosine Kinase Screening in Ischemic Heart Identifies ROR1 as a Potential Target for the Treatment of Ischemia J Heliste, I Paatero, A Jokilammi, D Chakroborty, C Stark, T Savunen, ... Circulation 136 (suppl_1), A19681-A19681, 2017 | | 2017 |
| Stem Cell Reports Resource The L1TD1 Protein Interactome Reveals the Impor tance of Post-transcriptional Regulation in Human Pluripotency EM Reddy, D Chakroborty, R Moulder, K Denessiouk | | |
| Nelly Rahkonen, Robert Moulder, Konstantin Denessiouk, Ras Trokovic, 2 Riikka Lund, Laura L. Elo, and Riitta Lahesmaa MR Emani, E Närvä, A Stubb, D Chakroborty, M Viitala, A Rokka | | |
Klaus EleniusVerified email at utu.fi
